<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657874</url>
  </required_header>
  <id_info>
    <org_study_id>RCT 002/2017</org_study_id>
    <nct_id>NCT04657874</nct_id>
  </id_info>
  <brief_title>Bromelain and Escin in the Reduction of Postoperative Sequelae in Periodontal and Implant Surgery</brief_title>
  <official_title>Association Between Bromelain and Escin in the Reduction of Postoperative Sequelae in Periodontal and Implant Surgery: Randomized Clinical Trial, Placebo-controlled, Double-blind</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of L'Aquila</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Leonardo Mancini</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tommaso Pizzolante</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of L'Aquila</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial will be performed in parallel, placebo controlled, triple-blind&#xD;
      to evaluate the effectiveness of the association Bromelina and Horse-chestnut (titrated in&#xD;
      escin) (Noflogo®, Mavenpharma s.r.l., Rome, Italy) in the management of post trauma-surgery&#xD;
      following surgery periodontal and implant surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At least 50 volunteers between the ages of 18 and 50, will be enlisted, with the need to&#xD;
      perform one of the interventions described above and that fall within the criteria of&#xD;
      inclusion.&#xD;
&#xD;
      The study will be carried out in accordance with the Helsinki Declaration on In Vivo Studies&#xD;
      and will be initiated with the approval of the Internal Review Board of the University of&#xD;
      L'Aquila.&#xD;
&#xD;
      The protocol follows the guidelines of the CONSORT Statement for parallel studies and will be&#xD;
      recorded on the data base clinicaltrials.gov.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Actual">May 27, 2021</completion_date>
  <primary_completion_date type="Actual">May 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Triple blind randomization and computer-based random allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Edema - Cheek Volume</measure>
    <time_frame>Baseline</time_frame>
    <description>The distance between the angle of the mouth and the lobe of the ear and the distance between the outer side of the eye and the angle of the jaw, following the bulge of the cheek. In addition, where possible, a facial scanner has been used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Edema - Cheek Volume</measure>
    <time_frame>Post-surgical - 30 min</time_frame>
    <description>The distance between the angle of the mouth and the lobe of the ear and the distance between the outer side of the eye and the angle of the jaw, following the bulge of the cheek. In addition, where possible, a facial scanner has been used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Edema - Cheek Volume</measure>
    <time_frame>2 days</time_frame>
    <description>The distance between the angle of the mouth and the lobe of the ear and the distance between the outer side of the eye and the angle of the jaw, following the bulge of the cheek. In addition, where possible, a facial scanner has been used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Edema - Cheek Volume</measure>
    <time_frame>7 days</time_frame>
    <description>The distance between the angle of the mouth and the lobe of the ear and the distance between the outer side of the eye and the angle of the jaw, following the bulge of the cheek. In addition, where possible, a facial scanner has been used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trismus - Vertical Opening</measure>
    <time_frame>Baseline</time_frame>
    <description>A calibre has been used to measure vertical opening.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trismus - Vertical Opening</measure>
    <time_frame>Post-surgical - 30 min</time_frame>
    <description>A calibre has been used to measure vertical opening.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trismus - Vertical Opening</measure>
    <time_frame>2 days</time_frame>
    <description>A calibre has been used to measure vertical opening.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trismus - Vertical Opening</measure>
    <time_frame>7 days</time_frame>
    <description>A calibre has been used to measure vertical opening.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain - (VAS)</measure>
    <time_frame>Baseline</time_frame>
    <description>The patient fills in the visual analog scale. This scale has values from 0 to 10 where 0 indicates &quot;no pain&quot; and 10 indicates &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain - (VAS)</measure>
    <time_frame>Post-surgical - 30 min</time_frame>
    <description>The patient fills in the visual analog scale. This scale has values from 0 to 10 where 0 indicates &quot;no pain&quot; and 10 indicates &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain - (VAS)</measure>
    <time_frame>2 days</time_frame>
    <description>The patient fills in the visual analog scale. This scale has values from 0 to 10 where 0 indicates &quot;no pain&quot; and 10 indicates &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain - (VAS)</measure>
    <time_frame>7 days</time_frame>
    <description>The patient fills in the visual analog scale. This scale has values from 0 to 10 where 0 indicates &quot;no pain&quot; and 10 indicates &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Edema</condition>
  <condition>Swelling Lips &amp; Face</condition>
  <arm_group>
    <arm_group_label>Bromelain and Escin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bromelains and Escin Oral Tablet</intervention_name>
    <description>Supportive care after oral surgery</description>
    <arm_group_label>Bromelain and Escin</arm_group_label>
    <other_name>Noflogo®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet without the active principle</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No signs of gingival inflammation;&#xD;
&#xD;
          -  FMBS and FMPS ≤ 20% after non-surgical causal therapy (Only for patients undergoing&#xD;
             periodontal surgery)&#xD;
&#xD;
          -  Smokers have to indicate how many cigarettes they smoke and how long have they been&#xD;
             smoking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gingival inflammation&#xD;
&#xD;
          -  Positive anamensis for relevant systemic pathologies (renal, cardiovascular, hepatic,&#xD;
             infectious, neoplastic and diabetological)&#xD;
&#xD;
          -  Treatment with anti-inflammatory and/or antibiotics in the two weeks preceding the&#xD;
             start of the trial&#xD;
&#xD;
          -  History of allergy to one or more components of the medication to be tested&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of L'Aquila, Division of Periodontology</name>
      <address>
        <city>L'aquila</city>
        <state>AQ</state>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of L'Aquila</investigator_affiliation>
    <investigator_full_name>Enrico Marchetti</investigator_full_name>
    <investigator_title>Prof. Enrico Marchetti</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

